Antipsychotic drug-induced weight gain mediated by histamine H1receptor-linked activation of hypothalamic AMP-kinase
- 27 February 2007
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 104 (9), 3456-3459
- https://doi.org/10.1073/pnas.0611417104
Abstract
The atypical antipsychotic drugs (AAPDs) have markedly enhanced the treatment of schizophrenias but their use has been hindered by the major weight gain elicited by some AAPDs. We report that orexigenic AAPDs potently and selectively activate hypothalamic AMP-kinase, an action abolished in mice with deletion of histamine H1 receptors. These findings may afford a means of developing more effective therapeutic agents and provide insight into the hypothalamic regulation of food intake.This publication has 45 references indexed in Scilit:
- AMP-Activated Protein Kinase as a Drug TargetAnnual Review of Pharmacology and Toxicology, 2007
- Developing a head for energy sensing: AMP‐activated protein kinase as a multifunctional metabolic sensor in the brainThe Journal of Physiology, 2006
- AMP‐activated protein kinase – development of the energy sensor conceptJournal Of Physiology-London, 2006
- Olanzapine and Weight GainAmerican Journal of Psychiatry, 2005
- AMP-activated protein kinase: Ancient energy gauge provides clues to modern understanding of metabolismCell Metabolism, 2005
- Second-Generation (Atypical) Antipsychotics and Metabolic EffectsCNS Drugs, 2005
- On-Line Manuscript Submission and Peer ReviewPublished by Physicians Postgraduate Press, Inc ,2003
- Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinaseBiochemical Society Transactions, 2002
- Integration of NPY, AGRP, and Melanocortin Signals in the Hypothalamic Paraventricular Nucleus: Evidence of a Cellular Basis for the AdipostatNeuron, 1999
- Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptorsNature, 1995